<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31437330</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>257</EndPage><MedlinePgn>251-257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14063</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The prognostic value of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, compared to other prognostic factors of amyotrophic lateral sclerosis (ALS) at the time of diagnosis, remains unclear.</AbstractText><AbstractText Label="METHODS">Sera from ALS patients were prospectively collected at the first diagnostic visit in our centre. sNfL levels were determined by single molecule array in 207 ALS patients and in 21 healthy controls. The prognostic value of sNfL was compared with that of other known clinical prognostic factors using a Cox regression model and multivariate analysis.</AbstractText><AbstractText Label="RESULTS">Serum neurofilament light chain levels were higher in ALS patients than in controls (P&#xa0;&lt;&#xa0;0.0001). Seven parameters were predictive of death in ALS: older age, bulbar onset, higher ALS Functional Rating Scale revised (ALSFRS-R) score, greater weight loss, lower maximal inspiratory pressure, forced vital capacity and higher sNfL levels. A Cox regression model showed that sNfL (P&#xa0;&lt;&#xa0;0.0001), weight loss (P&#xa0;=&#xa0;0.040) and site at onset (P&#xa0;=&#xa0;0.048) were independent predictive factors of death. In a sub-cohort restricted to 139 patients with complete spirometry data, sNfL level (P&#xa0;&lt;&#xa0;0.005) and forced vital capacity (P&#xa0;=&#xa0;0.022) were independent factors predictive of death. In a subgroup of 142 patients in whom ALSFRS-R score was available at several time points, sNfL levels positively correlated with ALSFRS-R rate of decline (r&#xa0;=&#xa0;0.571, P&#xa0;&lt;&#xa0;10<sup>-12</sup> ).</AbstractText><AbstractText Label="CONCLUSIONS">Higher sNfL concentration is a strong and independent prognostic factor of death in ALS as early as the time of diagnosis.</AbstractText><CopyrightInformation>&#xa9; 2019 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thouvenot</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de Neurologie, CHU N&#xee;mes, CNRS, INSERM, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demattei</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>D&#xe9;partement d'Information M&#xe9;dicale, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Plateforme de Prot&#xe9;omique Clinique, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maceski-Maleska</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Plateforme de Prot&#xe9;omique Clinique, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirtz</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Plateforme de Prot&#xe9;omique Clinique, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juntas-Morales</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pageot</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esselin</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alphand&#xe9;ry</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratoire d'Immunologie, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>W</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1287-7355</Identifier><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, CHU Montpellier, INSERM, Univ Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Oct;15(10):557</RefSource><PMID Version="1">31506590</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2020 Nov;27(11):e65</RefSource><PMID Version="1">32189420</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">multivariate analysis</Keyword><Keyword MajorTopicYN="N">neurofilament light chain</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31437330</ArticleId><ArticleId IdType="doi">10.1111/ene.14063</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 639-649.</Citation></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et&#xa0;al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009; 10: 310-323.</Citation></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et&#xa0;al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018; 17: 423-433.</Citation></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, et&#xa0;al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol 2017; 264: 54-63.</Citation></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Survival prediction in amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol 2017; 17: 73.</Citation></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et&#xa0;al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017; 88: 2302-2309.</Citation></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et&#xa0;al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87: 12-20.</Citation></Reference><Reference><Citation>Tortelli R, Copetti M, Ruggieri M, et&#xa0;al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 2015; 22: 215-218.</Citation></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, et&#xa0;al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 2015; 86: 565-573.</Citation></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, et&#xa0;al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015; 84: 2247-2257.</Citation></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, et&#xa0;al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; 54: 1655-1661.</Citation></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et&#xa0;al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018; 90: e22-e30.</Citation></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et&#xa0;al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019; 90: 157-164.</Citation></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, et&#xa0;al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000; 57: 1171-1176.</Citation></Reference><Reference><Citation>Forbes RB, Colville S, Swingler RJ. Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement. Amyotroph Lateral Scler 2001; 2: 135-138.</Citation></Reference><Reference><Citation>Teunissen CE, Tumani H, Bennett JL, et&#xa0;al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011; 2011: 246412.</Citation></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et&#xa0;al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010; 28: 595-599.</Citation></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. http://www.R-project.org/ (accessed 20/12/2018).</Citation></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et&#xa0;al. Progression rate of ALSFRS-R-R at time of diagnosis predicts survival time in ALS. Neurology 2006; 66: 265-267.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018; 84: 130-139.</Citation></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et&#xa0;al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016; 79: 152-158.</Citation></Reference><Reference><Citation>Mandrioli J, Ferri L, Fasano A, et&#xa0;al. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 2018; 25: 861-868.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>